EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

VEGF ‐A Antisense Oligonucleotide Therapy Inhibits Corneal Neovascularisation and Enhances Graft Survival in Murine High‐Risk Corneal Transplantation

Wei Zhang iD, Christian Weile, Christoph Ullmer iD, Sascha Fauser iD, Felix Bock iD, Claus Cursiefen iD

Clinical & Experimental Ophthalmology · 2026-11 · 54 (8) · 1029-1040

DOI: 10.1111/ceo.70159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical & Experimental Ophthalmology, online erschienen am 09.09.2026. Verfasst von Wei Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Corneal Neovascularization, Vascular Endothelial Growth Factor A, Graft Survival, Disease Models, Animal. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation (german: Deutsche Forschungsgesellschaft DFG), Deutsche Forschungsgemeinschaft, EU COST Aniridia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To investigate, for the first time, whether an unconjugated VEGF‐A antisense oligonucleotide (ASO) can inhibit corneal neovascularisation and improve graft survival in a murine high‐risk corneal transplantation model.

Methods

A suture‐induced corneal neovascularisation model was established in BALB/c mice, followed by high‐risk corneal transplantation using C57BL/6 donor corneas. A VEGF‐A RNase H–recruiting ASO (gapmer) was delivered via subconjunctival injection, topical eye drops, or ex vivo preincubation of donor corneas. Blood vessels (BVs) and lymphatic vessels (LVs) were quantified by immunohistochemistry, and Vegfa mRNA expression was measured by qPCR. Immune cell profiles in draining lymph nodes (dLNs), focusing on regulatory T cells (Tregs) and dendritic cells (DCs), were analysed by flow cytometry. Graft survival was monitored for 8 weeks using Kaplan–Meier analysis.

Results

Subconjunctival and topical VEGF‐A ASO administration significantly suppressed corneal hemangiogenesis and lymphangiogenesis ( p < 0.05). Subconjunctival injection also induced regression of established vessels (BVs −21.76%, p = 0.0039; LVs −49.75%, p = 0.0110). Graft survival improved significantly after subconjunctival treatment ( p = 0.0438) and donor cornea preincubation ( p = 0.0148). Flow cytometry showed increased Treg frequency in dLNs following subconjunctival ASO administration ( p = 0.0293). Preincubation of donor corneas markedly reduced Vegfa mRNA levels ( p < 0.0001).

Conclusions

VEGF‐A–targeting ASO effectively inhibits corneal neovascularisation and improves graft survival in high‐risk transplantation. Local and ex vivo VEGF‐A inhibition using ASO represents a promising therapeutic strategy for controlling ocular neovascularisation and enhancing corneal transplant outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Corneal NeovascularizationVascular Endothelial Growth Factor AGraft SurvivalDisease Models, AnimalOligonucleotides, AntisenseCorneal TransplantationAngiogenesis InhibitorsAnimalsMiceMice, Inbred C57BLMice, Inbred BALB CRNA, MessengerT-Lymphocytes, RegulatoryFlow CytometryDendritic CellsInjections, IntraocularLymphangiogenesisFemaleReal-Time Polymerase Chain ReactionMale

Substanzen

Vascular Endothelial Growth Factor ARNA, Messengervascular endothelial growth factor A, mouseOligonucleotides, AntisenseAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Department of Ophthalmology, Hebei Eye Hospital, Hebei Key Laboratory of Ophthalmology, Xingtai, Hebei, China.
  • Department of Ophthalmology, Affiliated Hospital of Guizhou Medical University, Guizhou Medical University, Guiyang, China.
  • BioInnovation Institute, Copenhagen, Denmark.
  • Roche Pharma Research & Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.

ORCID-Profile: Wei Zhang, Christoph Ullmer, Sascha Fauser, Felix Bock, Claus Cursiefen

Förderung

  • German Research Foundation (german: Deutsche Forschungsgesellschaft DFG)
  • Deutsche Forschungsgemeinschaft
  • EU COST Aniridia
  • EU Horizon 2020 ARREST BLINDNESS
  • EU Horizon 2020 Restore Vision
  • Center for Molecular Medicine Cologne, University of Cologne
  • CECAD Cluster of Excellence, University of Cologne
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, W., Weile, C., Ullmer, C., Fauser, S., Bock, F., & Cursiefen, C. (2026). VEGF ‐A Antisense Oligonucleotide Therapy Inhibits Corneal Neovascularisation and Enhances Graft Survival in Murine High‐Risk Corneal Transplantation. Clinical & Experimental Ophthalmology, 54(8), 1029-1040. https://doi.org/10.1111/ceo.70159

Vancouver

Zhang W, Weile C, Ullmer C, Fauser S, Bock F, Cursiefen C. VEGF ‐A Antisense Oligonucleotide Therapy Inhibits Corneal Neovascularisation and Enhances Graft Survival in Murine High‐Risk Corneal Transplantation. Clinical & Experimental Ophthalmology. 2026;54(8):1029-1040. doi:10.1111/ceo.70159

BibTeX
@article{Zhang2026,
  author = {Zhang, Wei and Weile, Christian and Ullmer, Christoph and Fauser, Sascha and Bock, Felix and Cursiefen, Claus},
  title = {VEGF ‐A Antisense Oligonucleotide Therapy Inhibits Corneal Neovascularisation and Enhances Graft Survival in Murine High‐Risk Corneal Transplantation},
  journal = {Clinical & Experimental Ophthalmology},
  year = {2026},
  volume = {54},
  number = {8},
  pages = {1029--1040},
  doi = {10.1111/ceo.70159}
}
Kostenlos starten →